Heliyon, 2023 Background: Although vaccinations and antiviral drugs are widely used in the clinical treatment worldwide, there is little investigation on the clinical outcomes and effectiveness of oral Azvudine tablets (FNC) treatment in COVID-19 hospitalized patients.
Yanli Zhao +5 more
doaj +1 more source
Case Report: Four cases of SARS-CoV-2-associated Guillain-Barré Syndrome with SARS-CoV-2-positive cerebrospinal fluid detected by metagenomic next-generation sequencing: a retrospective case series from China [PDF]
, 2023 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is often absent or at low levels in the cerebrospinal fluid (CSF) of patients with previous SARS-CoV-2-associated Guillain-Barré syndrome (GBS).
Changshen Yu +10 more
core +1 more source
Azvudine therapy of common COVID‐19 in hemodialysis patients
Journal of Medical Virology, 2023 AbstractThere is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially on the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients.
Shunlai Shang +11 more
openaire +2 more sources
An update on SARS-CoV-2 clinical trial results—what we can learn for the next pandemic [PDF]
, 2023 The coronavirus disease 2019 (COVID-19) pandemic has claimed over 7 million lives worldwide, providing a stark reminder of the importance of pandemic preparedness.
Arman, Benediktus Yohan +4 more
core +2 more sources
Frontiers in Pharmacology, 2023 Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety.Methods: We conducted a retrospective cohort study involving
An-Hua Wei +7 more
doaj +1 more source
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds [PDF]
, 2023 © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Currently, it ...
Bártolo, Inês +2 more
core +1 more source
Epidemic and pandemic viral infections: Impact on tuberculosis and the lung [PDF]
, 2020 Major epidemics, including some that qualify as pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung. Tuberculosis (TB) remains the
Delogu G. +3 more
core +9 more sources
Analysis of risk factors and short-term prognostic factors of arrhythmia in patients infected with mild/moderate SARS-CoV-2 Omicron variant [PDF]
, 2023 BackgroundComplications, including arrhythmia, following severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection continue to be of concern. Omicron is the mainstream SARS-CoV-2 mutant circulating in mainland China.
Futao Zhang +11 more
core +1 more source
Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model [PDF]
, 2021 The outbreak of novel coronavirus pneumonia (COVID-19) caused thousands of deaths worldwide, and the number of total infections is still rising. However, the development of effective vaccine for this novel virus would take a few months. Thus it is urgent
Hu, Fan, Jiang, Jiaxin, Yin, Peng
core +1 more source
Neurological complications during the Omicron COVID-19 wave in China: A cohort study [PDF]
, 2023 Background and purpose: The aim was to investigate the neurological complications associated with coronavirus disease 19 (COVID-19) during the 2022 Omicron wave.
Chen, L +15 more
core